Bioventus (BVS) Cash from Investing Activities Growth (3y) (2023 - 2026)
Bioventus (BVS) Cash from Investing Activities Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.57 Bn | 193.97 Bn | 7.27 Bn | 17.83% |
| 2 | Stryker | 127.25 Bn | 123.77 Bn | 4.50 Bn | -6.23% |
| 3 | Medtronic | 118.81 Bn | 109.59 Bn | 6.41 Bn | -24.52% |
| 4 | Boston Scientific | 73.35 Bn | 72.81 Bn | 3.85 Bn | -32.54% |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | -68.12% |
| 6 | Dexcom | 34.28 Bn | 32.34 Bn | 830.00 Mn | 37.39% |
| 7 | GE HealthCare Technologies | 33.75 Bn | 31.64 Bn | 2.18 Bn | -11.04% |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 19.58% |
| 9 | Steris | 23.03 Bn | 22.55 Bn | 684.20 Mn | -17.67% |
| 10 | Bioventus | 964.22 Mn | 934.77 Mn | 105.67 Mn | -27.13% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 27, 2026 | -27.13% |
| Mar 28, 2026 | 66.35% |
| Dec 31, 2025 | 44.56% |
| Sep 27, 2025 | 79.68% |
| Jun 28, 2025 | 70.26% |
| Mar 29, 2025 | 43.88% |
| Dec 31, 2024 | 28.24% |
| Sep 28, 2024 | 83.07% |
| Jun 29, 2024 | 69.25% |
| Mar 30, 2024 | 72.22% |
| Dec 31, 2023 | 29.84% |
| Sep 30, 2023 | 51.42% |
| Jul 1, 2023 | 295.64% |
| Apr 1, 2023 | -222.06% |